Global ENDS Market Expected to Reach $250 Billion by 2022

Jul.04.2022
The global ENDS market is expected to reach $250.3 billion in 2022 with a CAGR of 25.6%.

Recently, The Business Research Company released a research report stating that the global market size of electronic nicotine delivery systems (ENDS) is expected to grow from $19.92 billion in 2021 to $25.03 billion in 2022, with a compound annual growth rate (CAGR) of 25.6%. The market growth mainly attributed to companies resuming operations and adapting to the new normal, while recovering from the impact of the COVID-19 pandemic. Earlier measures to combat COVID-19, including social distancing, remote work, and closure of business premises, had restrictive effects. The ENDS market, including e-cigarettes, is expected to reach $55.99 billion in 2026, with a CAGR of 22.3%.

 

The market being discussed in this report includes vaporizers, electronic cigarettes, and other electronic nicotine delivery systems (ENDS). Vaporizers cover electronic cigarette vaporizers, cannabis vaporizers, and medical vaporizers. Electronic cigarette types include disposable electronic cigarettes, rechargeable electronic cigarettes, and open-system electronic cigarettes.

 

The report covers 60 regions, including Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, United Arab Emirates, United Kingdom, United States, Venezuela, and Vietnam.

 

This article is compiled from third-party information for educational and communication purposes only. Copyright belongs to the original media and authors of the compiled information. If there is any infringement, please contact us for removal.

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Irish Cabinet to Consider Bill Banning Sale of Single-Use Vapes
Irish Cabinet to Consider Bill Banning Sale of Single-Use Vapes
Ireland’s Minister for Health, Jennifer Carroll MacNeill, will seek Cabinet approval today for the publication of the Public Health (Single-Use Vapes) Bill 2025, which proposes banning the retail sale of single-use or disposable vapes six months after becoming law. The measure aims to address the growing use of disposable vapes, particularly among young people, and close regulatory gaps around emerging nicotine products such as pouches.
Nov.18 by 2FIRSTS.ai
Illegal Market Surges After Kazakhstan Bans E-Cigarettes; Telegram Becomes the Main Trading Channel
Illegal Market Surges After Kazakhstan Bans E-Cigarettes; Telegram Becomes the Main Trading Channel
Since Kazakhstan banned e-cigarette sales in June 2024, transactions have gone underground, shifting to Telegram and some e-commerce platforms and making enforcement harder; related research indicates the ban has not significantly reduced demand.
Oct.20 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
NYC Reaches Settlement with E-Cigarette Distributors in Flavored Vape Crackdown
NYC Reaches Settlement with E-Cigarette Distributors in Flavored Vape Crackdown
New York City has reached settlement agreements with two e-cigarette wholesalers accused of selling flavored vapes illegally. The companies agreed to stop all flavored vape transactions in the city and face $1,000 fines for future violations. Litigation against other defendants in the broader case continues.
Nov.25 by 2FIRSTS.ai
Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment
Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment
Imperial Brands has launched its ZONE nicotine pouches in the UK, targeting the mainstream 9–12 mg nicotine strength segment. The brand debuts with five flavours at a recommended retail price of £6.50 per can. Mint variants currently account for around 70% of UK nicotine pouch sales, while fruit flavours are growing rapidly. ZONE will be distributed primarily through independent retail channels.
Nov.18 by 2FIRSTS.ai